WO2000078946A3 - Treatment of viral influenza with antisense oligonucleotides - Google Patents

Treatment of viral influenza with antisense oligonucleotides Download PDF

Info

Publication number
WO2000078946A3
WO2000078946A3 PCT/US2000/016810 US0016810W WO0078946A3 WO 2000078946 A3 WO2000078946 A3 WO 2000078946A3 US 0016810 W US0016810 W US 0016810W WO 0078946 A3 WO0078946 A3 WO 0078946A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral influenza
antisense oligonucleotides
inos
treatment
synthesis
Prior art date
Application number
PCT/US2000/016810
Other languages
French (fr)
Other versions
WO2000078946A2 (en
Inventor
Evan T Keller
Stefan Gravenstein
David Mark Hall
Original Assignee
Eastern Virginia Med School
Evan T Keller
Stefan Gravenstein
David Mark Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Virginia Med School, Evan T Keller, Stefan Gravenstein, David Mark Hall filed Critical Eastern Virginia Med School
Priority to AU63360/00A priority Critical patent/AU6336000A/en
Publication of WO2000078946A2 publication Critical patent/WO2000078946A2/en
Publication of WO2000078946A3 publication Critical patent/WO2000078946A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Abstract

A therapy for treating viral influenza entails inhibiting the synthesis of inducible nitric oxide synthase (iNOS) by means of using antisense oligonucleotides that hybridize with iNOS RNA. The resultant inhibition of iNOS synthesis in vivo reduces the production of NO, which in turn lessens damage to the lungs due to NO toxicity. This lessening of damage allows patients to recover more rapidly from a viral influenza infection, even if antisense oligonucleotides are administered more than 48 hours after the onset of a viral influenza infection.
PCT/US2000/016810 1999-06-17 2000-06-19 Treatment of viral influenza with antisense oligonucleotides WO2000078946A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63360/00A AU6336000A (en) 1999-06-17 2000-06-19 Treatment of viral influenza with antisense oligonucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13947999P 1999-06-17 1999-06-17
US60/139,479 1999-06-17

Publications (2)

Publication Number Publication Date
WO2000078946A2 WO2000078946A2 (en) 2000-12-28
WO2000078946A3 true WO2000078946A3 (en) 2001-05-03

Family

ID=22486862

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/016810 WO2000078946A2 (en) 1999-06-17 2000-06-19 Treatment of viral influenza with antisense oligonucleotides

Country Status (2)

Country Link
AU (1) AU6336000A (en)
WO (1) WO2000078946A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040162A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for lung diseases using antisense oligonucleotides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040162A1 (en) * 1995-06-07 1996-12-19 East Carolina University Method of treatment for lung diseases using antisense oligonucleotides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AKAIKE TAKAAKI ET AL: "Pathogenesis of influenza virus-induced pneumonia: Involvement of both nitric oxide and oxygen radicals.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 93, no. 6, 1996, pages 2448 - 2453, XP002156507, ISSN: 0027-8424 *
ARIMA HIDETOSHI ET AL: "Specific inhibition of nitric oxide production in macrophages by phosphorothioate antisense oligonucleotides.", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 86, no. 10, 1997, pages 1079 - 1084, XP002156509, ISSN: 0022-3549 *
KARUPIAH GUNASEGARAN ET AL: "Rapid interferon gamma-dependent clearance of influenza A virus and protection from consolidating pneumonitis in nitric oxide synthase 2-deficient mice.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 8, 19 October 1998 (1998-10-19), pages 1541 - 1546, XP002156508, ISSN: 0022-1007 *
MAEDA HIROSHI ET AL: "Multiple functions of nitric oxide in pathophysiology and microbiology: Analysis by a new nitric oxide scavenger.", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 56, no. 5, 1994, pages 588 - 592, XP000971906, ISSN: 0741-5400 *
SELLERI CARMINE ET AL: "Induction of nitric oxide synthase is involved in the mechanism of Fas-mediated apoptosis in haemopoietic cells.", BRITISH JOURNAL OF HAEMATOLOGY, vol. 99, no. 3, 1 December 1997 (1997-12-01), pages 481 - 489, XP000971900, ISSN: 0007-1048 *

Also Published As

Publication number Publication date
AU6336000A (en) 2001-01-09
WO2000078946A2 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
EP1160318A3 (en) Medicament for treatment of Duchenne muscular dystrophy
WO2007022073A3 (en) Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
WO2007103529A3 (en) Antisense antiviral compound and method for treating arenavirus infection
WO2003033657A3 (en) Antisense antiviral agent and method for treating ssrna viral infection
WO2005084192A3 (en) Novel 2’-c-methyl nucleoside derivatives
WO2007030691A3 (en) Antisense antiviral compound and method for treating picornavirus infection
WO2007030576A3 (en) Antisense antiviral compound and method for treating picornavirus infection
JP2015519891A5 (en)
ATE460481T1 (en) METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICATION FOR THE THERAPY OF A TUMOR DISEASE
WO2006047683A3 (en) Antisense antiviral compound and method for treating influenza viral infection
WO2001080843A3 (en) Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
EP1035870A4 (en) Compositions and methods for treatment of hepatitis c virus-associated diseases
WO2002076472A3 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
CN1545409A (en) Use of stilbene compounds in preparing medicaments for treating and preventing diabetes or diseases associated with retrovirus
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
CA2418479A1 (en) Prodrugs of betulinic acid derivatives for the treatment of cancer
WO2000049993A3 (en) Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
WO2003048315A3 (en) Antisense modulation of mdm2 expression
EP0745090A1 (en) Oligonucleotides with anti-respiratory syncytial virus activity
WO2021186396A3 (en) Tgf-beta inhibition, agents and composition therefor
WO2002039999B1 (en) Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
WO2003097050A3 (en) A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
WO2006019685A3 (en) Compounds and their preparation for the treatment of alzheimer's disease by inhibiting beta-amyloid peptide production
WO2000078946A3 (en) Treatment of viral influenza with antisense oligonucleotides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP